Day: August 6, 2024

Lantronix’s Percepxion Cloud Software Platform Honored as One of the Most Innovative IoT Products IRVINE, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in Compute and Connectivity IoT solutions, is proud to announce that its Percepxion™ Cloud IoT Edge Solutions platform has been honored with the prestigious 2024 IoT Evolution Product of the Year Award by IoT Evolution World, the leading online publication in IoT technologies. This esteemed award celebrates the most groundbreaking products and solutions in IoT as selected by the editors of IoT Evolution World. For Lantronix, being recognized underscores our unwavering commitment to advancing business efficiency and fostering innovation in the IoT sector with cutting-edge technology. Since its launch in February 2024, the Percepxion...

CALGARY, Alberta, Aug. 06, 2024 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX: DRT; OTC: DRTTF), a leader in industrialized construction, today announced the release of ICE Manager, the most significant update to its industry-leading software platform to date. This software update introduces two key components: the new ICE Manager and the Design Editor application, both developed to revolutionize user engagement with the ICE platform. These advancements streamline the update process and enable continuous value delivery, positioning DIRTT’s partners and clients at the forefront of industrialized construction technology. “The release of ICE Manager is an incredibly exciting milestone. This modernization of the ICE Software will ensure it remains the best specification and configuration...

TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company’s name has been changed from “Aeterna Zentaris Inc.” to “COSCIENS Biopharma Inc.”, effective as of August 6, 2024 (the “Name Change”). In addition, the Company announces that, effective as of August 9, 2024, the Company’s common shares (the “Common Shares”) will begin trading on the Toronto Stock Exchange (the “TSX”) and NASDAQ Capital Market (the “NASDAQ”) under the trading symbol “CSCI” and will concurrently cease...

AUSTIN, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) — Mondee Holdings, Inc. (Nasdaq: MOND) (“Mondee” or the “Company”), a leading travel marketplace and artificial intelligence (AI) technology company, announced that it will hold its webcast on the second quarter 2024 financial results for the period ended June 30, 2024 and its anticipated new financing, on Wednesday, August 14, 2024. A release shall accompany the webcast. The Company is rescheduling the webcast as a result of an agreement on principle terms with lenders for a refinancing which it is working diligently to close. The Company will host the live audio webcast at 5:30 a.m. (PT) / 7:30 a.m. (CT) / 8:30 a.m. (ET) on Wednesday, August 14, 2024, to discuss its financial results and anticipated long-term financing with the investment community. The webcast is expected to last...

Broadcast and Commercial Music Revenues Soar with 17.1% Organic Growth YoY Revenues increased 12.8% to $89.1 million in the first quarter of fiscal 2025 from $79.0 million in the first quarter of 2024; Adjusted EBITDA(1) improved 9.9% to $31.1 million in the first quarter of 2025 from $28.3 million in the first quarter of 2024. Adjusted EBITDA(1) by segment was $23.0 million or 40.4% of revenues for Broadcasting and Commercial Music, $9.9 million or 30.8% of revenues for Radio, and $(1.8) million for Corporate; Net income totaled $7.3 million, or $0.11 per share, in the first quarter of 2025 compared to $14.1 million, or $0.20 per share, in the first quarter of 2024; Adjusted net income(1) increased 17.2% to $13.9 million, or $0.20 per share, in the first quarter of 2025 from $11.9 million, or $0.17 per share, in the same period of 2024; Cash...

– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios’ Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion – – Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND® (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress – CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the Company will receive a total of $1.1 billion in milestone payments following the U.S. Food and Drug Administration (FDA) approval of vorasidenib for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or...